25P Association between the lung immune prognostic index (LIPI) and durvalumab consolidation outcomes in patients with locally advanced non-small cell lung cancer (NSCLC)

Authors :: UCL - SSS/DDUV/GECE - Génétique cellulaire
UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie
UCL - (SLuc) Service de pneumologie
Riudavets Melia, M.
Auclin, E.
Aboubakar Nana, Frank
Ponce Aix, S.
Dal Maso, A.
Bluthgen, V.
Mielgo, X.
Mussat, E.
Reyes, R.
Benítez, J.
Lupinacci, L.
Duchemann, B.
de Giglio, A.
Bautista, J.
Audigier-Valette, C.
Scheffler, M.
Campayo, M.
Besse, B.
Planchard, D.
Mezquita, L.
UCL - SSS/DDUV/GECE - Génétique cellulaire
UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie
UCL - (SLuc) Service de pneumologie
Riudavets Melia, M.
Auclin, E.
Aboubakar Nana, Frank
Ponce Aix, S.
Dal Maso, A.
Bluthgen, V.
Mielgo, X.
Mussat, E.
Reyes, R.
Benítez, J.
Lupinacci, L.
Duchemann, B.
de Giglio, A.
Bautista, J.
Audigier-Valette, C.
Scheffler, M.
Campayo, M.
Besse, B.
Planchard, D.
Mezquita, L.
Source :: Annals of Oncology, Vol. 32, no.Suppl 7, p. S1384 (2021)
Publication Year :: 2021
Abstract: BACKGROUND : The LIPI, based on pretreatment derived neutrophils/[leukocytes-neutrophils] ratio (dNLR) >3 and lactate dehydrogenase (LDH) >upper limit of normal (ULN), is associated with immune checkpoint inhibitors (ICI) outcomes in advanced non-small cell lung cancer (NSCLC). We aimed to assess if baseline LIPI correlates with durvalumab efficacy after chemoradiotherapy (ChRT) in the locally advanced setting. [...]

Tools